Description

Droxinavir CAS NO 159910-86-8 is a high-purity pharmaceutical intermediate and active ingredient of significant importance in modern therapeutic development. Its primary value lies in its role as a key building block for the synthesis of advanced antiviral and protease inhibitor compounds. This product is essential for research institutions, contract development and manufacturing organizations (CDMOs), and pharmaceutical companies engaged in the development of novel antiviral therapies and other specialized active pharmaceutical ingredients (APIs).

Application

• Pharmaceutical Intermediate: A critical precursor in the multi-step synthesis of complex antiviral APIs and protease inhibitors.
• Antiviral Drug Research: Serves as a key scaffold for the discovery and development of new therapeutic agents targeting viral infections.
• Protease Inhibitor Synthesis: Used in the manufacture of compounds designed to inhibit specific viral proteases, crucial for viral replication.
• Contract Manufacturing: Supplied to CDMOs for the production of clinical trial materials and commercial-scale API batches under GMP conditions.
• Biochemical Research: Utilized in academic and industrial laboratories for studying enzyme kinetics and structure-activity relationships (SAR).
• Reference Standard: High-purity grades are suitable for use as analytical reference standards in quality control laboratories.

Basic Information

Product Name	Droxinavir
CAS No.	159910-86-8
Molecular Formula	Contact for details
Molecular Weight	Contact for details
Synonyms	Droxinavir; 159910-86-8; UNII-7K5F8VZ8Q0; 7K5F8VZ8Q0; SCHEMBL218422; BCP31833; ZINC000004254756; AKOS025310626; (2R,3S,5R)-2-(2,5-Difluorophenyl)-5-[6-methoxy-5-(trifluoromethyl)pyridin-3-yl]tetrahydro-2H-pyran-3-amine
EINECS	Contact for details

Quality Control

Our Droxinavir is manufactured under strict quality management systems. Each batch undergoes rigorous analytical testing, including chromatographic purity assays and identity confirmation, to ensure it meets the stringent requirements for pharmaceutical intermediates. Certificates of Analysis (COA) documenting purity, related substances, and other critical parameters are available for every shipment. We support development with GMP-compliant documentation and can tailor specifications to meet specific project needs.

Storage

Preserve in a tightly closed container, protected from light. Store in a cool, dry, and well-ventilated place at controlled room temperature (15-25°C). Due to its hygroscopic (moisture-sensitive) nature, the container must be kept tightly sealed after opening to prevent degradation from atmospheric moisture. Keep away from incompatible materials.

Specification

Item	Specification
Appearance	White to off-white powder
Identification (IR)	Conforms to reference spectrum
Identification (HPLC)	Retention time matches reference standard
Assay (HPLC)	≥ 98.0%
Related Substances (HPLC)	Total impurities ≤ 2.0% Any single impurity ≤ 0.5%
Water Content (KF)	≤ 1.0%
Residue on Ignition	≤ 0.1%

Note: Specifications can be tailored. Please contact us for the detailed technical data sheet of a specific grade.